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A B S T R A C T
Background: Despite the better clinical performance of second-generation drug-eluting stents (DES) 
when compared to first-generation DES in controlled trials, mainly due to reduction in thrombosis rate, it 
remains unclear whether this benefit extends to diabetic patients treated in the daily practice. We sought 
to compare the clinical outcomes of unselected diabetic patients treated with either sirolimus eluting 
stents - SES (first-generation DES) or everolimus-eluting stents - EES (second-generation DES).
Methods: Between January 2007 and October 2014 a total of 798 diabetic patients were treated with SES 
(n = 414) and EES (n = 384). Long-term clinical follow-up was achieved in 99,4% of the population and 
the groups were compared regarding the occurrence of major adverse cardiac events (MACE) and stent 
thrombosis.
Results: In both cohorts age was similar, and most patients were male. Stable coronary disease was the 
most frequent clinical presentation. The number of treated vessels (1.50 ± 0.62 vs. 1.52 ± 0.72; p = 0.88) 
and the total stent length (36.1 ± 20.4 vs. 37.7 ± 22.2 mm; p = 0.32) were similar between groups. Patients 
treated with EES showed lower rates of MACE (15% vs. 6.8%, p < 0.001), mainly due to a lower cardiac death 
(5.3% vs. 1.3%, p < 0.001). There was also less definitive/ probable thrombosis with the second generation 
DES (3.4% vs. 0.5%, p = 0.004).
Conclusions: In this single center experience, the use of EES was associated with reduced cardiac death and 
stent thrombosis. This benefit was mostly observed in the long-term follow-up.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Published by Elsevier Editora Ltda. 
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 
 
Desfechos clínicos tardios de pacientes diabéticos tratados com stents 
farmacológicos eluidores de sirolimus ou everolimus: uma análise do registro 
DESIRE
R E S U M O
Introdução: Stents farmacológicos (SF) de segunda geração demonstraram melhor desempenho clínico 
que os de primeira geração, sobretudo pela redução nas taxas de trombose, mas ainda não está claro se 
esse benefício se estende a diabéticos da prática diária. Objetivamos comparar o desempenho de pacientes 
diabéticos não selecionados tratados com SF eluidores de sirolimus (SES; primeira geração) vs. SF eluidores 
de everolimus (SEE; segunda geração).
Métodos: Entre 2007 e 2014, 798 diabéticos foram tratados com SES (n = 414) ou SEE (n = 384) e incluídos 
nesta análise. Seguimento clínico tardio foi obtido em 99,4% da população e os grupos foram comparados 
quanto à ocorrência de eventos cardíacos adversos maiores (ECAM) e trombose de stent.
Resultados: A idade da população foi semelhante, com predomínio do sexo masculino. Em ambas as coortes, 
a apresentação clínica mais frequente foi a doença coronária estável. Número de vasos tratados (1,50 ± 
0,62 vs. 1,52 ± 0,72; p = 0,88) e extensão total de stents (36,1 ± 20,4 mm vs. 37,7 ± 22,2 mm; p = 0,32) foram 
semelhantes. Os pacientes tratados com SEE apresentaram menores taxas de ECAM (15% vs. 6,8%; p < 0,001), 
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sobretudo à custa de menor mortalidade cardíaca (5,3% vs. 1,3%; p < 0,001). Observou-se também menor 
ocorrência de trombose de stent definitiva/provável com SF de segunda geração (3,4% vs. 0,5%; p = 0,004).
Conclusões: Nesta experiência unicêntrica, o uso de SEE em diabéticos mostrou-se com menor mortalidade 
cardíaca e trombose da endoprótese. Esse benefício se fez mais evidente no seguimento mais tardio.
© 2015 Sociedade Brasileira de Hemodinâmica e Cardiologia Intervencionista. Publicado por Elsevier Editora Ltda. 
Este é um artigo Open Access sob a licença de CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The presence of diabetes mellitus increases the risk of cardiovas-
cular disease by two- to four-fold1 and worsens the prognosis of 
treated individuals,2,3 regardless of coronary revascularization mo-
dality (surgical or percutaneous).
It is estimated that approximately 25% of patients treated with 
percutaneous coronary intervention (PCI) are diabetics.4 Even with 
the advent of drug-eluting stents (DES), which, compared to bare-
metal stents, greatly reduced restenosis rates,5-7 these individuals 
still have worse clinical outcomes, with higher rates of restenosis, 
stent thrombosis, acute myocardial infarction (AMI), and death, 
when compared to non-diabetic subjects.8
Although some controlled clinical trials have demonstrated the 
superiority of second-generation DES compared to first-generation 
devices, particularly in reducing thrombosis,9,10 is not yet clear 
whether this benefit extends to unselected diabetic patients treated 
in daily practice.
The present study aimed to compare late clinical outcomes of 
minimally selected diabetic patients treated with first- vs. second-
generation DES and included in the Drug-Eluting Stent In the REal 
world (DESIRE) Registry.
Methods
Protocol and study population
The details of the protocol and the initial results of the (DESIRE) 
Registry have been reported.11 The DESIRE Registry is a prospective, 
non-randomized, single-arm study with consecutive inclusion of 
patients in treatment, performed at a single institution (Hospital do 
Coração, Associação do Sanatório Sírio) from São Paulo (SP), with the 
aim of investigating the long-term clinical outcome of patients 
treated with DES. Since May 2002, PCI with DES has been used as the 
strategy of choice for patients referred for routine or emergency per-
cutaneous treatment in that institution. Patients with at least one 
lesion with stenosis > 50% and a favorable anatomy for PCI with 
stenting are included. By protocol, there are no limitations on the 
number of lesions and/or vessels that can be treated, and with 
respect to the number of DES implanted. The study is in accordance 
with the Declaration of Helsinki and was approved by the Research 
Ethics Committee of the institution.
In this analysis, only diabetic patients, whether or not using insu-
lin, and treated with first-generation sirolimus-eluting stents (SES, 
CypherTM, Cordis – Warren, USA) and second-generation everolimus-
eluting stents (EES, XIENCETM, Abbott Vascular, Santa Clara, USA; or 
PromusTM, Boston Scientific – Natick, USA) were included. Only pa-
tients treated from January 2007 onwards (when there was a change 
in antiplatelet protocol at the institution) were included; all patients 
received acetylsalicylic acid and thienopyridines for at least 12 
months following PCI.
Procedure
PCIs were performed according to current guidelines, and the fi-
nal strategy of the procedure was left to the operators’ discretion. 
Implant of multiple stents and/or treatment of multiple lesions (for a 
staged or non-staged procedure) were also allowed.
The antithrombotic protocol consisted of the use of two anti-
platelet agents: acetylsalicylic acid and clopidogrel. Pre-treatment 
with acetylsalicylic acid 200-500 mg and clopidogrel 300 mg was 
performed > 24 hours prior to intervention for elective cases, or 600 
mg of clopidogrel > 2 hours before the procedure for acute coronary 
syndrome without ST-segment elevation. After intervention, aspirin 
therapy was maintained indefinitely at a dose of 100-200 mg/day; 
clopidogrel 75 mg daily was maintained, starting from January 2007, 
during at least 12 months after PCI, according to recommendations 
of the Food and Drug Administration (FDA). During the procedure, 
intravenous heparin was administered (70-100 U/kg) to maintain an 
activated clotting time > 250 seconds (or > 200 seconds in the case of 
glycoprotein IIb/IIIa inhibitor administration). A 12-lead electrocar-
diogram was obtained before, immediately after and 24 hours after 
the procedure. Laboratory tests included cardiac enzymes (creatine 
phosphokinase [CPK] and creatine phosphokinase fraction MB [CK-
MB mass]) before (< 24 hours) and 18-24 hours after the procedure, 
and afterwards on a daily basis in the case of change, until hospital 
discharge.
Objectives, definitions and clinical follow-up
The primary objective of the study was to compare the occur-
rence of major adverse cardiac events (MACE) at late follow-up of 
diabetic patients treated with SES or EES. The combined endpoint of 
MACE included cardiac death, AMI, or ischemia-driven target lesion 
revascularization.
As a rule, all deaths were considered as of a cardiac origin, unless 
a non-cardiac cause could be clearly established by clinical and/or 
pathological study.
The diagnosis of AMI was based on the appearance of new patho-
logical Q waves in at least two contiguous leads on an electrocardio-
gram and/or an elevation of CK-MB mass > 3-fold the upper limit of 
normal.
Stent thrombosis was defined according to the Academic Research 
Consortium (ARC) as definite, probable, or possible, and was also 
classified according to temporal occurrence, including acute (< 24 
hours from the procedure), subacute (between 24 hours and 30 days), 
late (between 1 to 12 months), and very late (> 12 months) stent 
thrombosis.
Angiographic success was defined as a Thrombolysis in Myocar-
dial Infarction (TIMI) grade 3 final flow, no dissections, and residual 
stenosis < 20% by quantitative coronary angiography. A clinical fol-
low-up was performed at 1, 6, and 12 months after the procedure, 
and then annually, consisting of scheduled medical visits or of tele-
phone contacts, and conducted according to a pre-established pro-
tocol.
All reported adverse events, including stent thrombosis, were in-
dependently adjudicated by the Clinical Events Committee, includ-
ing two experienced professionals in clinical and invasive cardiology.
Statistical analysis
The variables are presented as absolute numbers and percentages 
or means and standard deviations. Categorical variables were com-
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pared using the Chi-squared test and, when indicated, Fisher’s exact 
test. Quantitative variables were compared using Student’s t-test. 
The occurrence of adverse events with respect to time was described 
by Kaplan-Meier curves that were compared by log-rank test. A 
p-value < 0.05 was considered significant. Analyzes were performed 
with STATA statistical software, version 10 (StataCorp LP, College 
Station, USA).
Results
Basic clinical features
Between January of 2007 and October of 2014, a total of 3,856 
patients were included in the DESIRE Registry. Of these, 1,280 
(33.2%) were diabetic. Most of this population (62.3%) was treated 
with SES (n = 414) or EES (n = 384) and were included in the present 
analysis.
The mean age of the treated population did not differ (61.7 ± 4.3 
years vs. 62.1 ± 4.6 years; p = 0.88), the majority were male, espe-
cially in the group treated with EES (69.8% vs. 80.5%; p = 0.01). The 
percentage of diabetics using insulin did not differ significantly 
between the two cohorts (13.5% vs. 15.1%; p = 0.61) and most of the 
population had a clinical presentation of stable coronary artery dis-
ease at the time of PCI (60.6% vs. 65.4%; p = 0.12). Table 1 shows the 
comparison among the main clinical variables in both groups.
Angiographic and procedural features
Approximately 40% of patients in both groups had multi-arterial 
disease, and a mean of 1.5 arteries/patient were treated, with no sig-
nificant difference between cohorts. However, the population treated 
with EES presented more complex angiographic features, such as a 
higher percentage of moderate/severe calcified lesions (36.7% vs. 
50.3%; p < 0.01) and ostial lesions (5.1% vs. 11.2%; p = 0.01).
The reference diameter (2.76 ± 0.4 mm vs. 2.8 ± 0.5 mm, p = 0.23) 
and the lesion length (21.1 ± 9.6 mm vs. 22.3 ± 10.1 mm; p = 0.11) did 
not differ between groups, but at the end of the procedure, higher 
acute gain and lower residual stenosis were observed among pa-
tients treated with EES. The total length of stents implanted per pa-
tient was 36.1 ± 20.4 mm vs. 37.7 ± 22.2 mm (p = 0.32). Table 2 details 
the major angiographic findings in both groups.
Late clinical outcomes
Clinical follow-up was obtained in 99.4% of patients.
In general, patients treated with second-generation DES (EES) 
showed less adverse cardiac events, with less mortality (5.3% vs. 
1.3%, p < 0.01) and tended to have a lower ischemia-driven target-
lesion revascularization (3.4% vs. 1.3%, p = 0.06). A lower incidence of 
definite/probable thrombosis with the use of EES (3.4% vs. 0.5%; p = 
0.01) was observed (Table 3).
The Figure 1 shows the cumulative incidence of MACE (panel A), 
cardiac death (panel B), and stent thrombosis (panel C) in both co-
horts.
Discussion
The main finding of this study is the fact that the second-genera-
tion EES demonstrated better efficacy and safety profile in the treat-
ment of diabetic patients in daily practice, with lower cardiac 
mortality and stent thrombosis compared to first-generation SES.
Diabetic patients tend to have a more exacerbated healing 
response, with neointimal overgrowth after treatment with PCI, a 
fact associated with higher restenosis rates in this population.12
Since preliminary studies, first-generation DES with sirolimus or 
paclitaxel, due to their high antiproliferative power, demonstrated 
superiority vs. bare metal stents in reducing in-stent lumen loss and 
hence the need for repeat revascularization procedures among dia-
betic patients.
The onset of second-generation DES potentially would further 
improve these results, especially when using EES. Studies in popula-
tions including diabetic and non-diabetic subjects showed 
Table 1
Basal clinical characteristics.
Variables
EES group  
(n = 414)
SES group  
(n = 384) p-value
Age, years 61.7 ± 4.3 62.1 ± 4.6 0.88
Male gender, n (%) 289 (69.8) 309 (80.5) 0.01
Diabetics using insulin, n (%) 56 (13.5) 58 (15.1) 0.61
Hypertension, n (%) 363 (87.7) 328 (85.4) 0.37
Dyslipidemia, n (%) 282 (68.1) 268 (69.8) 0.72
Currently smoking, n (%) 20 (4.8) 22 (5.7) 0.69
Prior AMI, n (%) 103 (24.9) 60 (15.6) 0.002
Prior PCI, n (%) 100 (24.2) 94 (24.5) 0.89
Prior CABG, n (%) 101 (24.4) 105 (27.3) 0.41
Severe renal impairment,* n (%) 32 (7.7) 28 (7.3) > 0.99
Clinical status, n (%) 0.12
Stable angina/silent ischemia 251 (60.6) 251 (65.4)
ACS without ST-segment elevation 154 (37.2) 123 (32.0)
ACS with ST-segment elevation 9 (2.2) 10 (2.6)
SES: sirolimus-eluting stent (first generation); EES: everolimus-eluting stent (second generation); 
AMI: acute myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery 
bypass graft; ACS: acute coronary syndrome.
* Creatinine clearance < 30 mL/min.
Table 2
Angiographic and procedural characteristics.
Variables
EES group  
(n = 414)
SES group  
(n = 384) p-value
Extent of disease, n (%) 0.72
One-artery disease 246 (59.5) 231 (60.1)
Two-artery disease 131 (31.6) 114 (29.7)
Three-artery disease 37 (8.9) 39 (10.2)
Number of vessels treated per patient 1.50 ± 0.62 1.52 ± 0.72 0.82
Number of stents per patient 1.79 ± 0.95 1.82 ± 0.98 0.57
Moderate/major calcification, n (%)a 152 (36.7) 193 (50.3) < 0.01
Ostial lesion, n (%)a 21 (5.1) 43 (11.2) 0.01
Venous graft lesion, n (%)a 19 (4.6) 29 (7.6) 0.21
Bifurcation, n (%)a 22 (5.3) 24 (6.2) 0.74
Restenotic lesion, n (%)a 23 (5.6) 13 (3.4) 0.16
Pre-PCI QCA 
Reference diameter of vessel, mm 2.76 ± 0.40 2.80 ± 0.50 0.23
Lesion length, mm 21.1 ± 9.6 22.3 ± 10.1 0.11
Diameter stenosis, % 70.0 ± 10.0 70.9 ± 9.6 0.34
Post-PCI QCA 
Acute gain, mm 1.81 ± 0.37 1.89 ± 0.39 0.01
Diameter stenosis, % 3.2 ± 2.5 2.5 ± 3.6 0.03
Total length of stents/patient, mm 36.1 ± 20.4 37.7 ± 22.2 0.32
SES: sirolimus-eluting stent (first generation); EES: everolimus-eluting stent (second generation); 
QCA: quantitative coronary angiography; PCI: percutaneous coronary intervention.
a Indicates the presence of at least one lesion with the characteristic evaluated.
Table 3
Late clinical outcomes.
Outcomes
EES group  
(n = 413)
SES group  
(n = 380) p-value
MACE, n (%) 62 (15) 26 (6.8) < 0.01
Cardiac death, n (%) 22 (5.3) 5 (1.3) < 0.01
Myocardial infarction, n (%) 26 (6.3) 16 (4.2) 0.17
Target lesion revascularization, n (%) 14 (3.4) 5 (1.3) 0.06
Definite/probable stent thrombosis, n (%) 14 (3.4) 2 (0.5) 0.01
EES: everolimus-eluting stent (second generation); SES: sirolimus-eluting stent (first generation); 
MACE: major adverse cardiac events.
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superiority of these stents vs. first-generation DES with paclitaxel, 
reducing thrombosis, target lesion revascularization, and even mor-
tality.9,10
However, when comparing EES versus first-generation SES, espe-
cially in diabetics, the results are not always consistent. In two ran-
domized clinical trials, ESSENCE-DIABETES13 and SORT-OUT IV14 
studies, it was demonstrated that EES was only non-inferior to SES in 
the treatment of patients with diabetes mellitus. In common, both 
studies showed a relatively short period of follow-up (12 and 18 
months, respectively); this may have been insufficient to detect differ-
ences between these devices, since, as seen in this analysis, they tend 
to occur especially after the sixth month and continue to occur later.
Corroborating this hypothesis, recent meta-analysis published by 
Yan et al. including approximately 1,500 patients with diabetes mel-
litus coming from ten controlled clinical trials, some of them with a 
long-term follow-up (> 2 years), demonstrated that the use of EES 
reduced mortality (RR = 0.58; 95%CI: 0.37-0.90; p = 0.01) and throm-
bosis (RR = 0.46; 95%CI: 0.22-0.95, p = 0.03) rates, when compared to 
first-generation DES with paclitaxel or sirolimus.15 These results are 
perfectly aligned with the findings of the present study, probably 
justified by the longer follow-up of Yan et al., particularly at a stage 
that dual antiplatelet therapy has been already discontinued for 
most individuals.
Limitations
This study has some limitations that must be observed. First, it is 
a non-randomized analysis. Moreover, although it is the largest Bra-
zilian cohort study comparing these two DES in diabetic patients, 
the numbers are still relatively small to permit more definite conclu-
sions. Finally, this represents the experience of a sole institution.
Conclusions
In this one-center experience, the use of second-generation EES 
in unselected diabetic patients was effective and safe, with lower 
rates of cardiac mortality and stent thrombosis when compared to 
first-generation SES. This benefit was seen mainly in late follow-up.
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